KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Koselugo was originally developed by Array BioPharma before AZ licensed the drug in 2003. The MEK 1/2 inhibitor endured ...

It also covers Novartis’ Mekinist (trametinib) in melanoma as well as other BRAF inhibitors and BRAF/MEK combination ...

A new study identifies key genetic vulnerabilities in glioblastoma stem cells, revealing subtype-specific dependencies that ...

Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to participate in the Stifel 2024 Healthcare Conference on Monday, November ...